Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nitric oxide generating formulations and kits

A kit and nitric oxide technology, which can be applied to medical preparations without active ingredients, medical preparations containing active ingredients, catheters, etc., can solve problems such as reducing immune response

Pending Publication Date: 2018-12-21
RGT UNIV OF MICHIGAN
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Defective NO production can lead to reduced immune response and / or microbial biofilm formation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nitric oxide generating formulations and kits
  • Nitric oxide generating formulations and kits
  • Nitric oxide generating formulations and kits

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Prepare two different solutions, one with 10 µM GSNO and one with 25 µM GSNO, in phosphate-buffered saline at physiological pH 7.4. These solutions did not include the additives disclosed herein.

[0074] The NO release profiles of the two solutions were measured at 37 °C by chemiluminescence detection and the results are shown in image 3 middle. As shown, both solutions produced NO continuously for more than 7 hours, and the solution containing the higher concentration of GSNO produced higher levels of NO. It should be noted that the NO levels observed for these solutions in this example, typically in the range of 5 ppbv to 40 ppbv, were compared with the gas levels actually observed in the sinus cavity by purging the released NO into the chemiluminescent NO analyzer with The test solution, which is continuously purged with a stream of nitrogen, is significantly diluted.

[0075] In 0.16M NaCl / 0.03M NaHCO 3 Two additional solutions, one with 100 µM GSNO and one wi...

Embodiment 2

[0078] preparation

[0079] In this example, using previously synthesized S-nitrosoglutathione (GSNO) alone or in combination with reduced L-glutathione (GSH, >98%) or L-ascorbic acid (Asc), prepared Several nasal preparations. Some formulations also include ethylenediaminetetraacetic acid (EDTA) and / or saline salts (NaCl and NaHCO 3 ). Components were mixed as dry powders and stored in 4 mL amber vials in the freezer (-18°C), at 4°C, at room temperature (RT, about 20°C to about 25°C), or at 37°C.

[0080] Different dry powder nasal formulations include GSNO; GSNO and GSH (1:1 molar ratio); GSNO, GSH and EDTA (1:1:0.1 molar ratio); GSNO:Asc (1:1 molar ratio); and GSNO:Asc :EDTA (1:1:0.1 molar ratio).

[0081] Dry powder nasal formulations of GSNO and EDTA were prepared with saline salt, and dry powder nasal formulations of GSNO and GSH were prepared with saline salt. Both formulations were prepared so that when diluted to 200 mL (with water), the final concentration of ...

Embodiment 3

[0113] 3A – Effect of GSNO:Asc(1:1) on Staphylococcus aureus biofilm disruption

[0114] Three strains of Staphylococcus aureus (SA817, SA1691 and SA 1681) were inoculated in 96-well microtiter plates (1×10 4 colony forming units / 100µl or CFU / 100µl) and cultured overnight. Remove planktonic bacteria and wash once with saline. Different concentrations of GSNO:ascorbic acid (1:1 or equimolar) were diluted in saline, and the saline solution (0.12M, 100 µl) was added to the bacterial biofilm retained on the well surface. Bacteria were incubated at room temperature (RT) for 4 hours, then biofilm density was determined by staining with crystal violet. Each bacterial strain was repeated 6 times, and experiments were carried out 3 times (i.e., for Figure 15 Each data point in N=6, plus or minus standard deviation). The experimental results are shown in Figure 15 middle. Specifically, Figure 15 The effect of GSNO / Asc on 3 different S. aureus isolates (SA817, SA1691 and SA 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
Login to View More

Abstract

An example of a nitric oxide generating formulation includes an S-nitrosothiol (RSNO) powder, a salt, and an additive. The additive is to control or accelerate a rate of release of nitric oxide (NO) from RSNO after the RSNO powder, the salt, and additive are dissolved into a liquid carrier. The nitric oxide generating formulation may be part of a kit that includes a container for dissolving the components into a liquid carrier. One of the kits may be used to prevent and / or treat sinonasal infections and another of the kits may be used to create antimicrobial lock solutions.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application Serial No. 62 / 299,850, filed February 25, 2016, the contents of which are hereby incorporated by reference in their entirety. Background of the invention [0003] In humans, nitric oxide (NO) can be produced by any of several isoforms of the enzyme nitric oxide synthase (NOS). NO is important for mammalian immune response or defense, and is responsible for the killing of Leishmania major by macrophages ( L. major ), Mycobacterium bovis ( M. bovis ) and Mycobacterium tuberculosis ( M. tuberculosis ) as well as cytotoxic agents in mechanisms used by many other species of bacteria. NO is also a potent antiviral agent, active against rhinoviruses that cause the common cold. NO is produced by immune cells (macrophages, neutrophils, lymphocytes, etc.) respiratory tract) from L-arginine. Defective NO production can lead to reduced immune responses and / or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L29/16A61L29/02A61K31/095
CPCA61K45/06A61K31/7036A61K9/0043A61K9/145A61K31/095A61K9/08A61K47/02A61K47/12A61K47/183A61P11/02A61P31/04A61P9/14A61K2300/00
Inventor M.E.迈尔霍夫G.劳特纳A.巴利杰帕利U.萨简任航
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com